AI assistant
Roivant Sciences Ltd. — Director's Dealing 2024
Sep 25, 2024
30587_dirs_2024-09-24_a6b53c77-e4b1-4dfa-9ea3-6b5f2f8c6d65.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2024-09-20
Reporting Person: Gline Matthew (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-09-20 | Common Shares | F | 10945 | $11.97 | Disposed | 18303800 | Direct |
| 2024-09-23 | Common Shares | M | 1550000 | $3.85 | Acquired | 19853800 | Direct |
| 2024-09-23 | Common Shares | S | 1983257 | $11.79 | Disposed | 17870543 | Direct |
| 2024-09-23 | Common Shares | J | 498539 | $11.97 | Disposed | 17372004 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-09-23 | Stock Option (Right to Buy) | $3.85 | M | 1550000 | Disposed | 2032-04-19 | Common Stock (1550000) | Direct |
Footnotes
F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
F2: The reporting person does not expect to sell additional shares of the Issuer in the near future.
F3: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F4: Represents the "net settlement" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options.
F5: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).